최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생물정신의학 = Korean journal of biological psychiatry, v.18 no.4, 2011년, pp.225 - 231
이재병 (고려대학교 의과대학 정신과학교실) , 함병주 (고려대학교 의과대학 정신과학교실) , 이화영 (순천향대학교 의과대학 정신과학교실) , 이민수 (고려대학교 의과대학 정신과학교실)
Objectives Atypical antipsychotics show better treatment efficacy, safety and tolerability than typical antipsychotics. Among the adverse events observed during treatment with antipsychotics, extrapyramidal syndrome (EPS) and negative symptoms has been greatly reduced. But still, weight gain is rece...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
정신분열병이란? | 정신분열병은 인간의 사고, 정동, 지각, 행동 등의 와해를 일으키는 질환으로서 증상뿐만 아니라 경과, 치료반응, 예후 면에서도 다양한 양상을 보인다. 정신분열병에 대한 일차적 치료는 항정신병 약물치료이며, 최근에는 음성증상에 효과적이고 부작용이 적은 비정형 항정신병 약물이 주로 사용되고 있다. | |
정신분열병에 대한 일차적 치료는? | 정신분열병은 인간의 사고, 정동, 지각, 행동 등의 와해를 일으키는 질환으로서 증상뿐만 아니라 경과, 치료반응, 예후 면에서도 다양한 양상을 보인다. 정신분열병에 대한 일차적 치료는 항정신병 약물치료이며, 최근에는 음성증상에 효과적이고 부작용이 적은 비정형 항정신병 약물이 주로 사용되고 있다.1)2) 비정형 항정신병 약물은 과거 주로 사용되었던 정형 항정신병 약물에 비하여 치료 효과와 부작용의 감소, 약물 순응도 면에서 우수한 결과를 보이며, 특히 추체외로 증상의 감소 및 음성증상의 개선에 좋은 효과를 보인다. | |
양성 및 음성 증후군 척도의 특징은? | 이 척도는 모두 30항목으로 되어 있고 형식적이며 반구조화된 임상적 면담과 기타 정보의 출처에 근거하여 양성척도(7개 항목), 음성척도(7개 항목) 및 일반정신병리척도(16개 항목)을 정량화할 수 있게 구성되어 있으며, 각 항목당 심한 정도에 따라 1점에서 7점까지 평가하게 되어 있다. 이 척도는 정신과 전문의에 의해 측정되었다. |
David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085-1096.
Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008;42:369-381.
Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58 Suppl 10:55-62.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999;60 Suppl 21:20-24.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-57.
Theisen FM, Linden A, Geller F, Schafer H, Martin M, Remschmidt H, et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 2001;35:339-345.
Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006;40:626-632.
Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22: 244-251.
Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005;5:3.
Garyfallos G, Dimelis D, Kouniakis P, Sidiropoulos N, Karastergiou A, Lavrentiadis G, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry 2003;18:320-321.
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
Muller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O; Amisulpride Study Group. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2002;22:554-560.
Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999;156:1744-1750.
Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Safety and tolerability of oral paliperidone extended- release tablets in elderly patients with schizophrenia: a doubleblind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16:31-43.
Jalenques I, Tauveron I, Albuisson E, Audy V. [Weight gain and clozapine]. Encephale 1996;22 Spec No 3:77-79.
Wetterling T, MUssigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19:316-321.
Kalucy RS. Drug-induced weight gain. Drugs 1980;19:268-278.
Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153:817-819.
Bai YM, Lin CC, Chen JY, Lin CY. Weight gain among patients on clozapine. Psychiatr Serv 1999;50:704-705.
Shrivastava A, Johnston ME. Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management. Mens Sana Monogr 2010;8:53-68.
Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24:59-73.
Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472.
Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3- 16.
Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008;100:70-85.
Chengappa KN, Sheth S, Brar JS, Parepally H, Marcus S, Gopalani A, et al. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. J Clin Psychiatry 1999;60:373-378.
Jaffe AB, Levine J. Efficacy and effectiveness of first- and secondgeneration antipsychotics in schizophrenia. J Clin Psychiatry 2003;64 Suppl 17:3-6.
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415- 427.
Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008;69:240-245.
Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32:683-697.
Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363.
Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002;28:5-16.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.